Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550 is registered in ClinicalTrials.gov with ArriVent BioPharma, Inc. as lead sponsor.

NCT NCT05607550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05607550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Lead sponsor
ArriVent BioPharma, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 1, 2023
Completion date
February 15, 2028
Enrollment
398 (actual)
Sites
208

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, egfr exon 20 mutations, metastatic non-small cell lung cancer